Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Immunotherapy

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2017-0129PMID 29370722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peptides Against Autoimmune Neurodegeneration.

  2017cited by this paper
• Roles of regulatory T cells in cancer immunity.

  2016cited by this paper
• Neuroimmunomodulation by allogeneic seminal vesicle fluid in CNS is sex-independent

  2016cited by this paper
• Cancer immunotherapy: the beginning of the end of cancer?

  2016cited by this paper
• Regulatory T cells in cancer immunotherapy

  2016cited by this paper
• Targeting regulatory T cells in tumors

  2016cited by this paper
• Whole tumor cell vaccines for glioma immunotherapy.

  2016cited by this paper
• Targeting Treg signaling for the treatment of autoimmune diseases.

  2015cited by this paper
• Autologous tumor lysate/Bacillus Calmette–Guérin immunotherapy as an adjuvant to conventional breast cancer therapy

  2015cited by this paper
• The role of regulatory T cells in cancer immunology

  2015cited by this paper
• Whole Tumor Antigen Vaccines: Where Are We?

  2015cited by this paper
• Anti-inflammatory effect of chymotrypsin to autoimmune response against CNS is dose-dependent.

  2014cited by this paper
• Allogeneic tumor cell vaccines

  2014cited by this paper
• Seminal vesicle fluid ameliorates autoimmune response within central nervous system

  2014cited by this paper
• Homeostatic control of regulatory T cell diversity

  2014cited by this paper
• Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.

  2012cited by this paper
• Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

  2012cited by this paper
• Whole cell vaccines--past progress and future strategies.

  2012cited by this paper
• Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

  2011cited by this paper
• Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

  2011cited by this paper
• Peptide immunotherapies in Type 1 diabetes: lessons from animal models.

  2011cited by this paper
• Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

  2011cited by this paper
• A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model.

  2010cited by this paper
• Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC

  2010cited by this paper
• GP96 C‐terminal improves Her2/neu DNA vaccine

  2010cited by this paper
• Whole tumor antigen vaccines.

  2010cited by this paper
• Development of IL-17-mediated delayed-type hypersensitivity is not affected by down-regulation of IL-25 expression.

  2010cited by this paper
• Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity1

  2009cited by this paper
• Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

  2009cited by this paper
• Regulatory T cells: how do they suppress immune responses?

  2009cited by this paper
• The effect of shark liver oil on the tumor infiltrating lymphocytes and cytokine pattern in mice.

  2009cited by this paper
• Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

  2009cited by this paper
• Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.

  2009cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Mechanism for maintaining homeostasis in the immune system of the intestine.

  2009cited by this paper
• Amelioration of delayed-type hypersensitivity responses by IL-27 administration.

  2008cited by this paper
• The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo.

  2008cited by this paper
• Dendritic cell vaccination and immune monitoring

  2008cited by this paper
• Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials

  2008cited by this paper
• Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines

  2008cited by this paper
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma

  2007cited by this paper
• Naturally occurring self-reactive CD4+CD25+ regulatory T cells: universal immune code.

  2007cited by this paper
• Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins.

  2006cited by this paper
• Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.

  2006cited by this paper
• Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo.

  2005cited by this paper
• Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells1

  2005cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Fatal attraction: tumors beckon regulatory T cells

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

  2004cited by this paper
• Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors.

  2004cited by this paper
• Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy.

  2004cited by this paper
• CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

  2003cited by this paper
• General network of natural autoantibodies as immunological homunculus (Immunculus).

  2003cited by this paper
• The Immunological Homunculus (Immunculus) in Normal State and Pathology

  2002cited by this paper
• Origin of regulatory T cells with known specificity for antigen

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1

  2002cited by this paper
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

  2001cited by this paper
• Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide

  2001cited by this paper
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

  1999cited by this paper
• Delayed type hypersensitivity: current theories with an historic perspective.

  1999cited by this paper
• Investigation of the role of delayed-type-hypersensitivity responses to myelin in the pathogenesis of Theiler's virus-induced demyelinating disease.

  1998cited by this paper
• The role of Fas/FasL in immunosuppression induced by human tumors

  1998cited by this paper
• Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

  1997cited by this paper
• Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions

  1997cited by this paper
• Delayed-type hypersensitivity reactions to tumor-associated antigens in colon carcinoma patients immunized with an autologous tumor cell/Bacillus Calmette-Guérin vaccine.

  1993cited by this paper
• Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

  1993cited by this paper
• Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

  1989cited by this paper
• Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors.

  1988cited by this paper
• Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors.

  1988cited by this paper
• Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones.

  1987cited by this paper
• Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.

  1986cited by this paper
• Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

  1986cited by this paper
• Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine.

  1984cited by this paper
• Augmentation of the human immune response by cyclophosphamide.

  1982cited by this paper
• Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.

  1980cited by this paper
• Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice.

  1979cited by this paper
• Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB.

  1975cited by this paper
• Impaired in vitro lymphocyte transformation in Hodgkin's disease.

  1965cited by this paper

• Helper T cell subsets: Development, function and clinical role in hypersensitivity reactions in the modern perspective

  2024cites this paper